Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) EBT (2020 - 2023)

Historic EBT for Immuneering (IMRX) over the last 4 years, with Q4 2023 value amounting to -$15.5 million.

  • Immuneering's EBT fell 1543.57% to -$15.5 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$54.8 million, marking a year-over-year decrease of 803.36%. This contributed to the annual value of -$54.8 million for FY2023, which is 849.74% down from last year.
  • As of Q4 2023, Immuneering's EBT stood at -$15.5 million, which was down 1543.57% from -$13.1 million recorded in Q3 2023.
  • Immuneering's 5-year EBT high stood at -$3.6 million for Q2 2020, and its period low was -$15.5 million during Q4 2023.
  • Moreover, its 4-year median value for EBT was -$11.5 million (2022), whereas its average is -$10.2 million.
  • Per our database at Business Quant, Immuneering's EBT plummeted by 12162.34% in 2021 and then plummeted by 81.48% in 2023.
  • Immuneering's EBT (Quarter) stood at -$5.8 million in 2020, then tumbled by 88.02% to -$11.0 million in 2021, then dropped by 22.75% to -$13.5 million in 2022, then fell by 15.44% to -$15.5 million in 2023.
  • Its EBT stands at -$15.5 million for Q4 2023, versus -$13.1 million for Q3 2023 and -$12.3 million for Q2 2023.